Matrix metalloproteinase-9 expression in pterygium.

PURPOSE To assess matrix metalloproteinase (MMP)-9 expression in pterygium lesion. METHODS A prospective randomized clinical trial was done to evaluate the expression of matrix metalloproteinase in normal and in primary or recurrent pterygia in Tenon's capsule by immunohistochemical analysis and a computerized image analysis system. The data were submitted to statistical analysis. RESULTS Matrix metalloproteinase expression showed no difference in normal Tenon's capsule and in primary or recurrent pterygia. CONCLUSION The similar expression of the matrix metalloproteinase in normal Tenon's capsule and in primary or recurrent pterygia allowed us to conclude that matrix metalloproteinase is not implicated in the genesis or the recurrence of pterygium lesion.

[1]  D. Wakefield,et al.  Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. , 2000, Investigative ophthalmology & visual science.

[2]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.

[3]  L. Sobrin,et al.  Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. , 1999, Investigative ophthalmology & visual science.

[4]  P. Fuchs,et al.  Human papillomavirus DNA in conjunctival papilloma , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[5]  S. Tseng,et al.  Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterygium head fibroblasts. , 2001, Archives of ophthalmology.

[6]  S. Tseng,et al.  Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. , 2000, Investigative ophthalmology & visual science.

[7]  C. Karapetis,et al.  Matrix Metalloproteinase Inhibitors: Applications in Oncology , 2004, Investigational New Drugs.

[8]  B. Nielsen,et al.  Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[9]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[10]  M. E. Cameron.  Histology of pterygium: an electron microscopic study. , 1983, The British journal of ophthalmology.

[11]  B. Cilova-Atanasova.  The mastocyte reaction in pterygium. , 1971, Folia medica.

[12]  J. Woessner,et al.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  G. Schultz,et al.  Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. , 2001, Archives of ophthalmology.

[14]  S. Tseng,et al.  Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasis fibroblasts. , 2000, Investigative ophthalmology & visual science.

[15]  L. Matrisian,et al.  Metalloproteinases and their inhibitors in matrix remodeling. , 1990, Trends in genetics : TIG.

[16]  D. Wakefield,et al.  Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. , 1997, The American journal of pathology.